Core Viewpoint - The introduction of patent execution insurance for Hunan Biyuan Biotechnology Co., Ltd. represents a significant step in protecting core technologies and encouraging innovation in the biotechnology sector [1][2]. Group 1: Company Insights - Hunan Biyuan has successfully insured two core biological technology patents with a total coverage amount of 1.6 million yuan, supported by the Changsha Economic Development Zone [1]. - The insurance allows the company to focus on research and innovation without the burden of potential legal costs associated with patent infringement [2]. Group 2: Industry Trends - The insurance industry is increasingly becoming an accelerator for technological innovation by offering specialized products like research failure insurance and intellectual property insurance [2]. - The launch of the first intellectual property insurance in Hunan reflects China Pacific Insurance's commitment to supporting the high-quality development of the real economy and emerging industries such as integrated circuits, biomedicine, artificial intelligence, and low-altitude economy [2].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 癌细胞通过 肿瘤细胞外囊泡 （TEV） 介导的细胞间和组织间通讯，促进肿瘤的生长和转移。抑制 TEV 是抑制肿瘤转移的一种很有前景的策略；然而，有效且有 选择性地抑制 TEV 仍具有挑战性。 近日，南方医科大学生物医学工程学院 汪枭睿 教授团队 （ 苗贵凤 博士和 商展豪 硕士为论文共同第一作者） 在 Nature 子刊 Nature Cancer 上发表了题为： Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles 的研究论文。 该研究开发了一种能够追踪并破坏 肿瘤细胞外囊泡 （TEV） 的 脂化纳米光敏剂，实现 同时抑制 肿瘤的生长和转移 。 在这项新研究中，研究团队采用邻近亲水性分子工程策略开发了 棕榈酸表面展示纳米颗粒 。出乎意料的是，这些脂质化纳米颗粒不仅能够被肿瘤细胞高效摄取并 在细胞内分布，而且还与肿瘤细胞外囊泡 （TEV） 的生成相结 ...

Core Insights - The article discusses advancements in the field of cyclic peptide libraries, particularly focusing on the DNA-encoded library technology (DELT) which enhances the screening and discovery of novel cyclic peptides with superior properties [1][2]. Group 1: Technology and Methodology - DELT allows for the rapid construction and screening of large compound libraries by linking specific nucleic acid tags to peptide molecules, providing an efficient and cost-effective platform for high-throughput screening of cyclic peptides [1]. - Researchers designed and synthesized eight cyclic peptide sub-libraries, collectively forming a super library containing approximately 100 million different cyclic peptide molecules, utilizing various cyclization methods [2]. Group 2: Research Findings - In screening for the tumor-related protein MDM2, multiple sub-libraries exhibited a consistent enrichment pattern, with specific amino acid sequences showing high binding affinity, achieving a maximum binding activity (Ki) of 11 nM [2]. - The study revealed that some cyclic peptide combinations, which had low enrichment in single sub-libraries, demonstrated good activity after off-DNA synthesis, indicating that single sub-library screening may underestimate the potential of high-activity molecules [2]. Group 3: Specific Case Studies - For the GIT1 screening, no consistent enrichment pattern was observed across different sub-libraries, leading to the identification of two cyclic peptide compounds, one of which effectively blocked the interaction with β-PIX [3]. - The research emphasized the importance of using multiple methods, such as competitive screening and in vitro experiments, to comprehensively validate the authenticity and specificity of the screened compounds [3]. Group 4: Publication and Support - The research findings were published in JACS Au under the title "Influence of Macrocyclization Strategies on DNA-Encoded Cyclic Peptide Libraries," and the work received support from the National Natural Science Foundation of China [3].

研发投入，催生出5款有潜力的临床阶段创新产品。 裘霁宛 ◎记者 王墨璞嘉 在生物医药领域，有一个"双十定律"：一款创新药从启动研发到上市，平均成本超过10亿美元，研发时 间超过10年。但是，荃信生物董事会主席裘霁宛带领公司走出一条打破这一定律的路径：以不到13亿元 这家聚焦自免领域的生物医药企业，不仅通过精准研发实现"小资金撬动大成果"，更以开放合作构建起 覆盖研发、临床、商业化的产业链"朋友圈"，并在2025年以5.55亿美元的海外授权交易叩开国际市场的 大门。从本土研发到全球布局，荃信生物是如何用效率与创新重构行业逻辑？ "做创新药是一个去风险的过程，创新药在早期研发端、临床试验端、生产端、质量控制端、用人端等 都存在着风险，企业要对这些风险有正确的认知。"裘霁宛在近日接受上海证券报记者专访时透露，正 是凭借对风险的深刻认知，荃信生物走出了一条"精准投入—生态协同—国际破局"的差异化成长道路。 小资金撬动大成果 高投入、高门槛，生物医药领域长期以来存在着"双十定律"。在这样的行业背景下，裘霁宛却实现了连 续成功创业。 2008年，裘霁宛开启首次创业，创立江苏泰康生物医药有限公司，凭借数千万元打造出4款即将 ...

Group 1 - The company, Degute, announced on June 29 that it is planning a major asset restructuring involving the issuance of shares and cash payment to acquire assets and raise supporting funds [2][4] - The transaction is expected to constitute a significant asset restructuring but will not lead to a change in the actual controller of the company [2][4] - The target company for this transaction is Haowei Cloud Computing Technology Co., Ltd., an international software and IT service provider [5][6] Group 2 - Degute's stock will be suspended from trading starting June 30, 2025, to ensure fair information disclosure and protect investor interests [4] - The company is required to disclose the transaction plan within 10 trading days, by July 14, 2025, and if not completed, the stock will resume trading on the same date [4] - As of June 27, 2025, Degute's stock price increased by 4.36%, closing at 22.27 yuan per share, with a total market capitalization of nearly 3.4 billion yuan [7] Group 3 - The company has signed a letter of intent with major shareholders of Haowei Technology, indicating a preliminary agreement to acquire control of the company [6] - The formal transaction agreement will take precedence over the letter of intent if there are any inconsistencies [6] - The company has a global sales network and serves various industries, including chemicals, energy, metallurgy, and waste treatment [5]

来源：中国新闻网 中新网昆明6月23日电 (记者 韩帅南)记者23日从中国科学院昆明动物研究所获悉，近期，该所何永捍团 队联合上海药物研究所张翾团队，研发新型肝纤维化靶向干预策略——肝脏靶向蛋白降解剂 (LIVTAC)，可有效控制早期肝纤维化和抑制晚期肿瘤的进展。 作为肝硬化和肝癌的早期阶段，肝纤维化(Hepatic fibrosis)是所有慢性肝病向终末期发展的必经病理阶 段。目前，针对肝纤维化的治疗药物匮乏，临床治疗主要停留在病因控制阶段。因此，探索肝纤维化的 新型干预手段，有望从根源上降低中晚期肝病的发生率，改善患者的长期生存率。 LIVTAC抑制肝细胞癌示意图。中国科学院昆明动物研究所 供图 前期，中国科学院昆明动物研究所何永捍团队联合上海药物研究所张翾团队，利用肝脏特异高表达的去 唾液酸糖蛋白受体(Asialoglycoprotein receptor, ASGPR)，将PROTAC分子与ASGPR配体偶联，成功开发 出肝脏靶向的蛋白降解剂(Liver-targeting chimera, LIVTAC)。LIVTAC主要在肝脏被摄取和释放，可精准 降解肝内靶蛋白，特异杀伤肝癌细胞，从而有效抑制肝癌 ...

ISM3412是一款高口服生物利用度、高选择性的强效MAT2A（甲硫氨酸腺苷转移酶2A）抑制剂，其研 发流程由英矽智能自有生成化学平台Chemistry42赋能。该候选药物通过抑制MAT2A，降低S-腺苷甲硫 氨酸（SAM）这一细胞功能必需成分的水平，进而针对性杀伤MTAP缺失的癌细胞，同时保护健康细 胞。考虑到MTAP缺失突变广泛存在于非小细胞肺癌（NSCLC）、胰腺癌、膀胱癌等多种实体瘤，该策 略有望提供创新治疗方案。 该项I期临床研究分为剂量递增试验和剂量选择优化两大部分，受试者将每日一次接受ISM3412口服治 疗。除针对ISM3412的安全性、耐受性、药代动力学/药效动力学特性和初步抗肿瘤疗效评估外，此项 研究还将确定后续研究的推荐剂量。截至目前，该试验已在中国组长单位，即中国医学科学院肿瘤医院 完成了首例受试者入组和第一剂量队列的剂量限制性毒性（DLT）观察。 通过整合先进的AI和自动化技术，英矽智能在实际应用案例中展现出效率提升，为AI驱动的药物研发 树立了标杆。与传统药物研发通常需要2.5-4年的时间周期相比，英矽智能在2021至2024年间的自研项 目，从立项到提名临床前候选药物（PCC）的 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-024 成都先导药物开发股份有限公司 为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 被担保人：Vernalis (R&D) Limited（以下简称"Vernalis"），系成都先导药 物开发股份有限公司（以下简称"成都先导"或"公司"）的全资子公司。 ? Vernalis 拟继续承租位于英国剑桥郡大阿宾顿格兰塔公园 GP3 的房产 （以 下简称"租赁物业"）作为办公场所用于研发和运营，与 BMR GRANTA PARK PROPCO LIMITED（一家注册于英国马恩岛的公司，以下简称"BMR"）拟签署 《复归租约》。租赁期限自 2026 年 9 月 29 日至 2028 年 3 月 28 日。基本租金为： 自 2027 年 9 月 29 日起，每年 1,023,347.55 英镑（不含增值税）。本次租赁项下， 公司将为 Vernalis 按照《复归租约》的约定支付所有款项及义务提供担保（以下 简称"本次担保 ...

智通财经APP获悉，近期，港股生物医药板块持续回暖，百奥赛图(02315)凭借独特的"创新动物模型+抗 体分子转让"双轮商业模式，犹如一匹黑马，股价表现格外引人注目，一路高歌猛进，其估值也随之经 历着重塑的过程。截至6月18日，百奥赛图股价从去年11月底部的5.6港币一路飙升至21.8港币，涨幅近 300%，今年年内涨幅也已超过150%，远远跑赢恒生指数及恒生科技指数涨幅。 这一变化的背后，是百奥赛图以全球领先的基因编辑技术为基础，以创新动物模型业务为增长引擎，并 逐步强化抗体分子转让开发作为另一增长引擎的成果。通过提供具有高技术壁垒的动物模型产品，以及 向全球药企提供具有自主知识产权的高潜力抗体分子，百奥赛图始终坚持底层技术创新，持续强化自身 作为Biotech企业的核心属性，走出了一条既不同于传统CRO公司，也有别于传统Biotech公司的新型发 展路径。其股价的强劲走势，直观地反映出市场对公司未来发展前景的高度看好，也体现了市场对百奥 赛图发展路径的充分认可。 创新动物模型业务：深厚根基，铸就全球领先地位 百奥赛图自成立以来，便专注于底层技术研发，经过多年的精心耕耘，已经在创新动物模型领域建立起 了深厚 ...

Core Viewpoint - The traditional drug development model faces multiple challenges such as low efficiency, long cycles, and high failure rates, while AI is deeply reshaping the paradigm of biopharmaceutical research. However, the lack of structured, high-quality, and reusable research data resources severely restricts the value of AI algorithms in new drug development [1] Group 1: Challenges in Biomedicine - Current biomedical research in China faces challenges including a late start in data-intensive research, a lack of quality data resources, and high barriers to algorithm innovation and tool integration, which do not meet the needs for rapid modeling, precise prediction, and target identification under AI [2] - There is a disconnection between positive genetic data from humans and reverse genetic research from model organisms, preventing effective utilization of research resources [2] Group 2: AI and Phenotypic Data - Human phenotypic data and model organism phenotypic data are key nodes connecting "gene-phenotype-disease" and provide a real biological basis for AI algorithms to achieve mechanism modeling and target prediction [2] - The establishment of high-quality platforms for phenotypic data and model organisms will play an increasingly important role in the future, producing data for model training as demand increases [4] Group 3: Institutional Initiatives - Fudan University is building a resource library for experimental mice, integrating all animal facilities and planning to establish an online database for easier access [3] - The Bio-OS intelligent biological analysis tool developed by the Guangzhou National Laboratory team aims to address issues faced by researchers in data analysis, such as high development thresholds and low reusability [4] Group 4: Collaboration and Standardization - South Model Biology is collaborating with the Shanghai International Human Phenotype Group to explore standardization in phenotypic data analysis and ensure the provision of high-quality phenotypic data [4] - A proposal was made to establish "Shanghai Gene Engineering Mouse Experiment Standards" to unify model genetic backgrounds and phenotypic data collection standards [4] Group 5: Expert Participation - The seminar gathered authoritative experts and industry representatives from the fields of gene editing, phenomics, and AI computing, including professors and researchers from Fudan University and South Model Biology [5]